CeeNU

This page contains recent news articles, when available, and an overview of CeeNU but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

CeeNU (when available)

Pharmacology and use:
Although it is generally agreed that CeeNU alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins. For use as a single agent in addition to other treatment modalities to treat brain tumors and Hodgkin's disease

Mechanism Of Action:
Lomustine is a highly lipophilic nitrosourea compound which undergoes hydrolysis in vivo to form reactive metabolites. These metabolites cause alkylation and cross-linking of DNA. Other biologic effects include inhibition of DNA synthesis and some cell cycle phase specificity. Nitrosureas generally lack cross-resistance with other alkylating agents

News Articles on Lomustine

Sweetie beats the odds  -  ‎Dec 28, 2009‎
..."We are going to go to once a month," she said, continuing with CeeNU, a brand name for the chemotherapy drug lomustine, and prednisolone. ... Poughkeepsie Journal

Lilly launches phase III trial of Enzastaurin  -  Mar 9, 2006
...safety and tolerability of enzastaurin, taken orally, versus CeeNU(R) (lomustine[CCNU]), a common oral chemotherapy used to treat this disease. ... News-Medical.net

Eli Lilly and Company  -  Sep 3, 2006
Alimta(R) (pemetrexed, Eli Lilly and Company) Gemzar(R) (gemcitabine HCl, Eli Lilly and Company) CeeNU(R) (lomustine [CCNU], Bristol Myers Squibb) (Logo: ... presseportal.ch

- Le Conseil de l'Europe et APC proposent un code en matière de …  -  Nov 12, 2007
...par la Commission Économique pour l'Europe des Nations Unies (CEENU), le Conseil de l'Europe et l'Association pour le progrès des communications (APC). ... APC.org

Lilly to Stop Enrollment in Clinical Trial  -  Dec 21, 2006
...versus CeeNU(R) (lomustine[CCNU]), a chemotherapy used to treat this disease. The primary endpoint is improvement in progression-free survival. ... insideindianabusiness.com

Open-Label Bites Drug Duo  -  Dec 19, 2008
Eli Lilly (NYSE: LLY) also has a phase 3 trial testing its drug candidate enzastaurin against Bristol-Myers Squibb's (NYSE: BMY) CeeNU for a similar tumor ... fool.com

Press Release: Eli Lilly and Company Stops Trial Of Brain Cancer Drug  -  Dec 20, 2006
...versus CeeNU(R) (lomustine[CCNU]), a chemotherapy used to treat this disease. The primary endpoint is improvement in progression-free survival. ... FierceBiotech

Lung cancer: as deadly as ever? Pharmacists should heed the call to …  -  Sep 4, 2006
...etoposide/cisplatin, cydophosphamide/doxorubicin/vin- cristine (CAV), lomustine (CeeNU, Bristol-Myers Squibb)/methotrexate, paditaxel, and topotecan. ... $4.95 - Drug Topics - ECNext

Press Release: Lilly Launches Phase III Trial of Targeted Cancer...  -  Mar 9, 2006
...safety and tolerability of enzastaurin, taken orally, versus CeeNU(R) (lomustine[CCNU]), a common oral chemotherapy used to treat this disease. ... Pay-Per-View - PR Newswire Europe - HighBeam Research

Clinical Trials; Eli Lilly launches phase 3 trial of targeted oral...  -  Apr 12, 2006
...safety and tolerability of enzastaurin, taken orally, versus CeeNU (lomustine[CCNU]), a common oral chemotherapy used to treat this disease. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones

Lilly initiates Ph III GBM Enzastaurin trial.(Eli Lilly and Co.)(gliob...  -  Mar 20, 2006
...safety and tolerability of the oral serine-threonine kinase inhibitor versus CeeNU (lomustine), a common oral chemotherapy for GBM. ... $4.95 - Pharma Marketletter - ECNext

Lilly inicia un ensayo Fase III de un nuevo medicamento contra el...  -  Mar 9, 2006
...la tolerancia de enzastaurina, tomada oralmente, versus CeeNU® (lomustina [CCNU]), una quimioterapia oral común, utilizada para tratar esta enfermedad. ... acceso.com

Brand Names/Synonyms:
CeeNU is also known by the following brand names and/or synonymsBelustine; CCNU; CCRIS 860; CHEMBANK4359; Ccnu [Chloroethyl Nitrosoureas]; Cecenu; Ceenu; Ceenu®; Chloroethylcyclohexylnitrosourea; Cinu; Cyclohexyl Chloroethyl Nitrosourea; HSDB 6519; ICIG 1109; Lomustina [Inn-Spanish]; Lomustine; Lomustine [Usan:Ban:Inn]; Lomustinum [Inn-Latin]; RB 1509; SRI 2200; [Inn-Spanish]

Drug Category:
CeeNU is categorized under the following by the FDA: Antineoplastic Agents; ATC:L01AD02

Dosage Forms:
CAPSULES

Absorption:
Rapidly and completely absorbed (in 30-60 minutes)

Interactions:
[an error occurred while processing this directive]

Chemical IUPAC Name:
1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.